You can view the research column published every month by SMC Laboratories.
2025.01.30
Gut Microbiome As a Target For NASH Therapeutics Study
We introduce the development of drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) focusing on …
READ MORE
2025.01.30
Drug efficacy study in NASH mouse model
Today we would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH…
READ MORE
2025.01.30
Introduction of the paper using NASH model mouse
One of our clients, Kagawa University, has published the results of a study using our non-alcoholic steatohepa…
READ MORE
2025.01.30
Drug Efficacy Studies in NASH Mouse Model_TGF-b neutralizing antibody
Today, we would like to introduce a study published by our client using our STAM™ mouse model (Okrah et al., n…
READ MORE
2025.01.30
Clinically correlated adipose tissue in liver disease model
MASH (Metabolic Dysfunction-Associated Steatohepatitis) is the progressive form of MASLD. The multiple …
READ MORE
2025.01.30
Relationship between DAMPs/PAMPs and pathogenesis of STAM mice
Today, we would like to share with you the correlation between our proprietary STAMTM model for NASH-HCC, and …
READ MORE
2025.01.30
Fibrosis-related factors and pathogenesis of STAM mice
Today, we would like to introduce the correlation between our proprietary STAMTM model and fibrosis-related fa…
READ MORE
2025.01.30
Wnt/β-catenin in STAM: How does it correlate to human liver cancer?
We would like to share with you the HCC-related gene expression data of our proprietary MASH-HCC model (STAMTM…
READ MORE
2025.01.29
Potential MASH biomarker in NASH-HCC model
We would like to introduce the data for a serological marker from our MASH model (STAMTM model). Hepato…
READ MORE
2025.01.29
Fibrosis markers in the STAM model
We would like to introduce a non-invasive fibrosis marker. Currently, the most reliable method for MASH…
READ MORE
